AUS
NZ
UK
CA
USA
IND
Highlights
- Institutional investors increase holdings in Quest Diagnostics, signaling strong confidence.
- Analysts from Barclays and Morgan Stanley adjust price targets, reflecting market sentiment.
- Quest Diagnostics maintains a solid financial position with stable revenue and dividends.
Quest Diagnostics Incorporated is a major provider of diagnostic testing and laboratory services, playing a crucial role in the healthcare industry. The company continues to attract institutional investments and positive ratings from financial firms, reflecting its strong market presence. With steady financial performance and strategic growth, it remains a key player in its sector. Quest Diagnostics Incorporated is part of NYSE Healthcare Stocks.
Institutional Investment Activity
Institutional investors continue to show strong interest in Quest Diagnostics (NYSE:DGX). Nisa Investment Advisors LLC increased its stake by 4.0% in the fourth quarter, bringing total holdings to approximately $1.59 million. Other firms, such as Versant Capital Management and Sentry Investment Management, have also expanded their positions. Institutional investors collectively hold 88.06% of Quest Diagnostics' stock, reflecting confidence in the company's market position.
Analyst Ratings and Price Adjustments
Analysts have revised their ratings and price targets for Quest Diagnostics in response to market conditions. Barclays recently raised its target price from $154.00 to $168.00, while Truist Financial and Morgan Stanley followed suit with similar upward adjustments. The overall sentiment includes a mix of hold and buy ratings, with an average price target of $172.15. These updates suggest positive expectations for the company's financial performance and competitive standing.
Financial Metrics and Stock Performance
Quest Diagnostics opened at $159.94 in its most recent trading session. The company has a market capitalization of $17.85 billion and a P/E ratio of 21.50. Liquidity ratios remain stable, with a quick ratio of 1.17 and a current ratio of 1.25, demonstrating the company’s ability to manage short-term obligations. Quest Diagnostics also offers consistent shareholder returns, recently declaring a quarterly dividend of $0.75 per share, equating to an annualized dividend of $3.00 and a yield of 1.88%. The dividend payout ratio stands at 40.32%, highlighting a balanced approach to financial management.
Business Operations and Market Presence
Quest Diagnostics provides diagnostic services across multiple healthcare segments. Its portfolio includes routine clinical testing, advanced diagnostic solutions, and pathology services. The company operates both domestically and internationally, serving healthcare providers, hospitals, and corporate clients. With a strong market presence and a focus on innovation, Quest Diagnostics continues to expand its service offerings to meet evolving industry demands.
Quest Diagnostics remains a significant player in the healthcare sector, with strong institutional backing and continued market presence. The company’s financial stability and expanding diagnostic solutions reinforce its role as a leader in the industry.
